Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis

Journal of Immunology

Volumn 190, Issue 9, 2013, Pages 4535-4541

  Othy, Shivashankar ^a,b   Hegde, Pushpa ^a,c   Topçu, Selma ^a,b   Sharma, Meenu ^a,c   Maddur, Mohan S ^a,b   Lacroix Desmazes, Sebastien ^a,b,d,e   Bayryand, Jagadeesh ^a,b,d,e   Kaveri, Srini V ^a,b,d  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR IIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MAMMALIAN TARGET OF RAPAMYCIN; PODOPLANIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL POLARITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; EFFECTOR CELL; FEMALE; IMMUNOMODULATION; LYMPHATIC DRAINAGE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL;

ADMINISTRATION, INTRAVENOUS; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; ENCEPHALITIS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOGLOBULINS, INTRAVENOUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; RECEPTORS, IGG; RECEPTORS, LYSOSPHINGOLIPID; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TOR SERINE-THREONINE KINASES;

EID: 84876783124     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201965     Document Type: Article

References (42)

1. Zhu, J., H. Yamane, and W. E. Paul. 2010. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 28: 445-489.
2. Codarri, L., G. Gyülvészi, V. Tosevski, L. Hesske, A. Fontana, L. Magnenat, T. Suter, and B. Becher. 2011. RORgt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12: 560-567.
3. Korn, T., E. Bettelli, M. Oukka, and V. K. Kuchroo. 2009. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27: 485-517.
4. Miossec, P., T. Korn, and V. K. Kuchroo. 2009. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361: 888-898.
5. Sakaguchi, S., M. Miyara, C. M. Costantino, and D. A. Hafler. 2010. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10: 490-500.
6. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775-787. (Pubitemid 351707693)
7. Seite, J. F., Y. Shoenfeld, P. Youinou, and S. Hillion. 2008. What is the contents of the magic draft IVIg? Autoimmun. Rev. 7: 435-439.
8. Tha-In, T., J. Bayry, H. J. Metselaar, S. V. Kaveri, and J. Kwekkeboom. 2008. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 29: 608-615.
9. Dalakas, M. C. 2002. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59(Suppl 6): S13-S21. (Pubitemid 36076544)
10. Nimmerjahn, F., and J. V. Ravetch. 2008. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26: 513-533. (Pubitemid 351600384)
11. Achiron, A., I. Kishner, I. Sarova-Pinhas, H. Raz, M. Faibel, Y. Stern, M. Lavie, M. Gurevich, M. Dolev, D. Magalashvili, and Y. Barak. 2004. Intravenous im-munoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch. Neurol. 61: 1515-1520. (Pubitemid 39350261)
12. Gold, R., M. Stangel, and M. C. Dalakas. 2007. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat. Clin. Pract. Neurol. 3: 36-44. (Pubitemid 46056032)
13. Humle Jorgensen, S., and P. S. Sorensen. 2005. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J. Neurol. Sci. 233: 61-65. (Pubitemid 40804817)
14. Achiron, A., R. Margalit, R. Hershkoviz, D. Markovits, T. Reshef, E. Melamed, I. R. Cohen, and O. Lider. 1994. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J. Clin. Invest. 93: 600-605.
15. Ephrem, A., S. Chamat, C. Miquel, S. Fisson, L. Mouthon, G. Caligiuri, S. Delignat, S. Elluru, J. Bayry, S. Lacroix-Desmazes, et al. 2008. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111: 715-722.
16. Yang, X. O., R. Nurieva, G. J. Martinez, H. S. Kang, Y. Chung, B. P. Pappu, B. Shah, S. H. Chang, K. S. Schluns, S. S. Watowich, et al. 2008. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29: 44-56.
17. Pashov, A., C. Dubey, S. V. Kaveri, B. Lectard, Y. M. Huang, M. D. Kazatchkine, and B. Bellon. 1998. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur. J. Immunol. 28: 1823-1831. (Pubitemid 28271698)
18. Jäger, A., V. Dardalhon, R. A. Sobel, E. Bettelli, and V. K. Kuchroo. 2009. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomy-elitis with different pathological phenotypes. J. Immunol. 183: 7169-7177.
19. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141. (Pubitemid 41541791)
20. McGeachy, M. J. 2011. GM-CSF: the secret weapon in the T(H)17 arsenal. Nat. Immunol. 12: 521-522.
21. Peters, A., L. A. Pitcher, J. M. Sullivan, M. Mitsdoerffer, S. E. Acton, B. Franz, K. Wucherpfennig, S. Turley, M. C. Carroll, R. A. Sobel, et al. 2011. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35: 986-996.
22. Anthony, R. M., T. Kobayashi, F. Wermeling, and J. V. Ravetch. 2011. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475: 110-113.
23. Schwab, I., M. Biburger, G. Kronke, G. Schett, and F. Nimmerjahn. 2012. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur. J. Immunol. 42: 826-830.
24. Lapointe, B. M., L. M. Herx, V. Gill, L. M. Metz, and P. Kubes. 2004. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 127: 2649-2656. (Pubitemid 39627374)
25. Glatigny, S., R. Duhen, M. Oukka, and E. Bettelli. 2011. Cutting edge: loss of a4 integrin expression differentially affects the homing of Th1 and Th17 cells. J. Immunol. 187: 6176-6179.
26. Rothhammer, V., S. Heink, F. Petermann, R. Srivastava, M. C. Claussen, B. Hemmer, and T. Korn. 2011. Th17 lymphocytes traffic to the central nervous system independently of a4 integrin expression during EAE. J. Exp. Med. 208: 2465-2476.
27. Spiegel, S., and S. Milstien. 2011. The outs and the ins of sphingosine-1-phosphate in immunity. Nat. Rev. Immunol. 11: 403-415.
28. Ruvinsky, I., and O. Meyuhas. 2006. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem. Sci. 31: 342-348. (Pubitemid 43903237)
29. Miron, V. E., J. A. Hall, T. E. Kennedy, B. Soliven, and J. P. Antel. 2008. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am. J. Pathol. 173: 1143-1152.
30. Choi, J. W., S. E. Gardell, D. R. Herr, R. Rivera, C. W. Lee, K. Noguchi, S. T. Teo, Y. C. Yung, M. Lu, G. Kennedy, and J. Chun. 2011. FTY720 (fin-golimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. USA 108: 751-756.
31. Haas, J., M. Maas-Enriquez, and H. P. Hartung. 2005. Intravenous immunoglobu-lins in the treatment of relapsing remitting multiple sclerosis-results of a retrospective multicenter observational study over five years. Mult. Scler. 11: 562-567. (Pubitemid 41387701)
32. Maddur, M. S., J. Vani, P. Hegde, S. Lacroix-Desmazes, S. V. Kaveri, and J. Bayry. 2011. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol. 127: 823-830.e821-827.
33. Weyand, C. M., P. J. Kurtin, and J. J. Goronzy. 2001. Ectopic lymphoid or-ganogenesis: a fast track for autoimmunity. Am. J. Pathol. 159: 787-793. (Pubitemid 32847167)
34. Samuelsson, A., T. L. Towers, and J. V. Ravetch. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486. (Pubitemid 32097072)
35. Kaneko, Y., F. Nimmerjahn, M. P. Madaio, and J. V. Ravetch. 2006. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203: 789-797.
36. Chiba, K., Y. Yanagawa, Y. Masubuchi, H. Kataoka, T. Kawaguchi, M. Ohtsuki, and Y. Hoshino. 1998. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160: 5037-5044. (Pubitemid 28215340)
37. Liu, G., S. Burns, G. Huang, K. Boyd, R. L. Proia, R. A. Flavell, and H. Chi. 2009. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat. Immunol. 10: 769-777.
38. Liao, J. J., M. C. Huang, and E. J. Goetzl. 2007. Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate. J. Immunol. 178: 5425-5428. (Pubitemid 46674335)
39. Liu, G., K. Yang, S. Burns, S. Shrestha, and H. Chi. 2010. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat. Immunol. 11: 1047-1056.
40. Kazatchkine, M. D., and S. V. Kaveri. 2001. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345: 747-755.
41. Wu, R., Y. Shoenfeld, Y. Sherer, M. Patnaik, E. Matsuura, B. Gilburd, T. Koike, and J. B. Peter. 2003. Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations-possible immunomodulation of atherosclerosis. Autoimmunity 36: 91-97. (Pubitemid 36394878)
42. De Groot, A. S., L. Moise, J. A. McMurry, E. Wambre, L. Van Overtvelt, P. Moingeon, D. W. Scott, and W. Martin. 2008. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112: 3303-3311.